• Home
  • Welcome
  • CAD & Treatments
  • Donation
  • Resources
  • Webinar Resources
  • Register Web Series
  • Latest News & Events
  • Members
  • Specialists
  • Media
  • Clinical Trials
  • Our Stories
  • Stay In The Know
  • Medical Advisors
  • Contact Us
  • Privacy & Policies
  • E-Learning Education
  • Impact ISPOR
  • Observational Study
  • More
    • Home
    • Welcome
    • CAD & Treatments
    • Donation
    • Resources
    • Webinar Resources
    • Register Web Series
    • Latest News & Events
    • Members
    • Specialists
    • Media
    • Clinical Trials
    • Our Stories
    • Stay In The Know
    • Medical Advisors
    • Contact Us
    • Privacy & Policies
    • E-Learning Education
    • Impact ISPOR
    • Observational Study
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • Welcome
  • CAD & Treatments
  • Donation
  • Resources
  • Webinar Resources
  • Register Web Series
  • Latest News & Events
  • Members
  • Specialists
  • Media
  • Clinical Trials
  • Our Stories
  • Stay In The Know
  • Medical Advisors
  • Contact Us
  • Privacy & Policies
  • E-Learning Education
  • Impact ISPOR
  • Observational Study

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

CLINICAL TRIALS

BIVV020 - A Safety and Tolerability Study of BIVV020 in Adults with Cold Agglutinin Disease Phase 1 Sanofi Genzyme

https://clinicaltrials.gov/ct2/show/NCT04269551 

Recruiting 

Estimated Completion Date November 2021


 BIVV009 - (Sutimlimab - press release May 14, 2020 ) A Study to Assess the Efficacy and safety of BIVV009 in Participants With Primary Cold Agglutinin Diseases Without A Recent History of Blood transfusion (Cadenza Study)  Phase 3  Sanofi Genzyme
https://clinicaltrials.gov/ct2/show/NCT03347422
Active, Not Recruiting
Estimated Completion Date December 2021 


Efficacy, Safety and Pharmacokinetics of Rilizabrutinib in Patients with Warm Autoimmue Hemolytic Anemia (wAIHA) This is a single group treatment, Phase 2 open-label, study to evaluate the efficacy, safety and pharmacokinetics of rilizabrutinib in adult patients with wAIHA.

ACT17209 - ClinicalTrials.gov 

As of September 29, 2021 Active, Not Recruiting YET


Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmunce Hemolytic Anemia (wAIHA).  Part A: To evaluate the safety and tolerability of subcutaneous injections of isatuximab in adults with wAIHA Part B: To evaluate the efficacy of the selected dose in adults with wAIHA 

ACT16832 - ClinicalTrials.gov

Active, Recruiting

We are writing to introduce ourselves and to share some exciting cold agglutinin disease (CAD) news.  Apellis is a development stage, global biopharmaceutical company that was established 10 years ago to combine courageous science, creativity, and compassion to deliver life-changing medicines for a broad range of serious diseases.  


Read Here for More:

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) Swedish Orphan Biovitrum. Click Here

Active, Recruiting Last Updated Post March 7, 2022  Estimated Completion Date June 2024


A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD)

Brief Summary:

Phase 3 - The purpose of the study is to determine the efficacy of pegcetacoplan administration compared to placebo in increasing hemoglobin (Hgb) level from baseline and avoiding transfusion in participants with primary cold agglutinin disease (CAD).

Click Here For Study

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. The safety and scientific validity of these studies is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the CADF Foundation. Please review our Privacy and Policies for more information. 

Copyright © 2022 Cold Agglutinin Disease Foundation - All Rights Reserved.

Privacy & Policies

Contact Us: info@cadfadvocacy.org

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept